Cullinan

Latest Posts

Goal response charge of 39% with manageable security profile in sufferers with non-small cell...

Market

Cullinan Therapeutics Publicizes Constructive Preliminary Information from Pivotal Part 2b REZILIENT1 Research of Zipalertinib By Investing.com – Coin Trolly